Mouse CDCP1 Protein

CUB domain containing protein 1 Protein Datasheet

CDCP1 Protein Product Information

• Synonym: CDCP1
• Protein Construction: A DNA sequence encoding the mouse CDCP1 (Q5U462) (Met1-Leu666) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
• Source: Mouse
• Expression Host: Human Cells

CDCP1 Protein QC Testing

• Purity: > 79 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ser 30
• Molecular Mass: The recombinant mouse CDCP1 /Fc is a disulfide-linked homodimer. The reduced monomer comprises 878 amino acids and has a predicted molecular mass of 98.8 kDa. The apparent molecular mass of the protein is approximately 117 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Formulation: Lyophilized from sterile PBS, pH7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CDCP1 protein

CDCP1 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CDCP1 Protein Description

CDCP1 is a transmembrane protein containing three extracellular CUB domains. This protein is found to be overexpressed in colon and lung cancers. Its expression level is correlated with the metastatic ability of carcinoma cells. This protein is located on the cell surface. It has been shown to be tyrosine phosphorylated in a cancer cell line. CDCP1 is a key regulator of EGF/EGFR-induced cell migration. It may be a rational approach to inhibit progression of cancers driven by EGFR signaling including those resistant to anti-EGFR drugs because of activating mutations in the RAS/RAF/MEK/ERK pathway. It may be involved in cell adhesion and cell matrix association. It also may play a role in the regulation of anchorage versus migration or proliferation versus differentiation via its phosphorylation. It has been taken as a novel marker for leukemia diagnosis and for immature hematopoietic stem cell subsets.

References

1. Conze T. et al., 2003, Ann N Y Acad Sci. 996 (1): 222-6.
2. Hooper JD. et al., 2003, Oncogene. 22 (12): 1783-94.
3. Scherl-Mostageer M. et al., 2001, Oncogene. 20 (32): 4402-8.